share_log

迪哲医药(688192.SH):DZD8586最新研究成果在第66届美国血液学会大会报告

Dizhe Pharmaceuticals (688192.SH): The latest research results of DZD8586 were reported at the 66th Annual Meeting of the usa Hematology Society.

Gelonghui Finance ·  Dec 8, 2024 23:44

On December 9, Geelong reported that Dixit Pharmaceuticals (688192.SH) announced at the 66th American Society of Hematology (ASH) Annual Meeting the latest research results summarizing the efficacy and safety of the company's independently developed novel non-covalent LYN/BTK dual-target inhibitor DZD8586 for the treatment of B-cell non-Hodgkin's lymphoma (B-NHL). DZD8586 can overcome classic BTK resistant mutations (C481X) and BTK kinase inactivation mutations, demonstrating encouraging anti-tumor efficacy in treating B-NHL, along with good safety and pharmacokinetic (PK) characteristics.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment